Claims
- 1. A peptide ketoamide compound of the formula:
- M.sub.1 -AA.sub.2 -AARES--CO--NH--R.sub.4
- or a pharmaceutically acceptable salt, wherein
- AARES represents AA.sub.1,
- M.sub.1 represents H, NH.sub.2 --CO--, NH.sub.2 --CS--, NH.sub.2 --SO.sub.2 --, X--NH--CO--, X.sub.2 N--CO--, X--NH--CS--, X.sub.2 N--CS--, X--NH--SO.sub.2 --, X.sub.2 N--SO.sub.2 --, X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO--, or X--O--CS--;
- X is selected from the group consisting of C.sub.1-10 alkyl, C.sub.1-10 fluoroalkyl, C.sub.1-10 alkyl substituted with J, C.sub.1-10 fluoroalkyl substituted with J, 1-admantyl, 9-fluorenyl, phenyl, phenyl substituted with K, phenyl disubstituted with K, phenyl trisubstituted with K, naphthyl, naphthyl substituted with K, naphthyl disubstituted with K, naphthyl trisubstituted with K, C.sub.1-10 alkyl with an attached phenyl group, C.sub.1-10 alkyl with two attached phenyl groups, C.sub.1-10 alkyl with an attached phenyl group substituted with K, C.sub.1-10 alkyl with two attached phenyl groups substituted with K, C.sub.1-10 alkyl with an attached phenoxy group, and C.sub.1-10 alkyl with an attached phenoxy group substituted with K on the phenoxy group;
- J is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-10 alkoxy, C.sub.1-10 alkylamine, C.sub.2-12 dialkylamine, C.sub.1-10 alkyl-O--CO--, C.sub.1-10 alkyl-O--CO--NH--, and C.sub.1-10 alkyl-S--;
- K is selected from the group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10 perfluoroalkyl, C.sub.1-10 alkoxy, NO.sub.2, CN, OH, CO.sub.2 H, amino, C.sub.1-10 alkylamino, C.sub.2-12 dialkylamino, C.sub.1 -C.sub.10 acyl, C.sub.1-10 alkoxy-CO--, and C.sub.1-10 alkyl-S--;
- AA.sub.2 is a side chain blocked or unblocked amino acid with the L configuration, D configuration, or no chirality at the .alpha.-carbon selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine, beta-alanine, norleucine, norvaline, alpha-aminobutyric acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperidine carboxylic acid), O-methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, NH.sub.2 --CH(CH.sub.2 CHEt.sub.2)--COOH, alpha-aminoheptanoic acid, NH.sub.2 --CH(CH.sub.2 -1-napthyl)-COOH, NH.sub.2 CH(CH.sub.2 -2-naphthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclohexyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopentyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclobutyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopropyl)-COOH, trifluoroleucine, and hexafluoroleucine;
- AA.sub.1 is a side chain blocked or unblocked amino acid with the L configuration, D configuration, or no chirality at the .alpha.-carbon selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfoxide, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine, beta-alanine, norleucine, norvaline, alpha-aminobutyric acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperidine carboxylic acid), O-methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, NH.sub.2 --CH(CH.sub.2 CHEt.sub.2)--COOH, alpha-aminoheptanoic acid, NH.sub.2 --CH(CH.sub.2 -1-napthyl)-COOH, NH.sub.2 CH(CH.sub.2 -2-napthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclohexyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopentyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclobutyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopropyl)-COOH, trifluoroleucine, and hexafluoroleucine; and
- R.sub.4 is selected from the group consisting of C.sub.3-20 cyclized alkyl with an attached phenyl group, C.sub.1-20 alkyl with an attached phenyl group substituted with K, C.sub.1-20 alkyl with an attached phenyl group disubstituted with K, C.sub.1-20 alkyl with an attached phenyl group trisubstituted with K, C.sub.3-20 cyclized alkyl with an attached phenyl group substituted with K, C.sub.1-10 alkyl with a morpholine ring attached through nitrogen to the alkyl, C.sub.1-10 alkyl with a piperidine ring attached through nitrogen to the alkyl, C.sub.1-10 alkyl with a pyrrolidine ring attached through nitrogen to the alkyl, C.sub.1-20 alkyl with an OH group attached to the alkyl, --CH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.2 OH, C.sub.1-10 alkyl with an attached 4-pyridyl group, C.sub.1-10 alkyl with an attached 3-pyridyl group, C.sub.1-10 alkyl with an attached 2-pyridyl group, --NH--CH.sub.2 CH.sub.2 -(4-hydroxyphenyl), and --NH--CH.sub.2 CH.sub.2 -(3-indolyl).
- 2. A peptide ketoamide compound for inhibiting serine and cysteine proteases selected from the group consisting of:
- (a) Z-Leu-Phe-CONH--(CH.sub.2).sub.2 Ph,
- (b) Z-Leu-Abu-CONH--(CH.sub.2).sub.2 Ph,
- (c) Z-Leu-Abu-CONH--(CH.sub.2).sub.3 --N(CH.sub.2 CH.sub.2).sub.2 O (morpholino),
- (d) Z-Leu-Abu-CONH--(CH.sub.2).sub.7 CH.sub.3,
- (e) Z-Leu-Abu-CONH--(CH.sub.2).sub.2 OH,
- (f) Z-Leu-Abu-CONH--(CH.sub.2).sub.2 O(CH.sub.2).sub.2 OH,
- (g) Z-Leu-Abu-CONH--(CH.sub.2).sub.17 CH.sub.3,
- (h) Z-Leu-Abu-CONH--CH.sub.2 --C.sub.6 H.sub.3 (OCH.sub.3).sub.2 (3,5 dimethoxy); and
- (i) Z-Leu-Abu-CONH--CH.sub.2 --C.sub.4 H.sub.4 N (4-pyridyl).
- 3. A peptide ketoamide compound of the formula:
- M.sub.1 -AA.sub.2 -AARES--CO--NH--R.sub.4
- or a pharmaceutically acceptable salt, wherein
- AARES represents AA.sub.1,
- M.sub.1 represents H, NH.sub.2 --CO--, NH.sub.2 --CS--, NH.sub.2 --SO.sub.2 --, X--NH--CO--, X.sub.2 N--CO--, X--NH--CS--, X.sub.2 N--CS--, X--NH--SO.sub.2 --, X.sub.2 N--SO.sub.2 --, X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO--, or X--O--CS--;
- X is selected from the group consisting of C.sub.1-10 alkyl, C.sub.1-10 fluoroalkyl, C.sub.1-10 alkyl substituted with J, C.sub.1-10 fluoroalkyl substituted with J, 1-admantyl, 9-fluorenyl, phenyl, phenyl substituted with K, phenyl disubstituted with K, phenyl trisubstituted with K, naphthyl, naphthyl substituted with K, naphthyl disubstituted with K, naphthyl trisubstituted with K, C.sub.1-10 alkyl with an attached phenyl group, C.sub.1-10 alkyl with two attached phenyl groups, C.sub.1-10 alkyl with an attached phenyl group substituted with K, C.sub.1-10 alkyl with two attached phenyl groups substituted with K, C.sub.1-10 alkyl with an attached phenoxy group, and C.sub.1-10 alkyl with an attached phenoxy group substituted with K on the phenoxy group;
- J is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-10 alkoxy, C.sub.1-10 alkylamine, C.sub.2-12 dialkylamine, C.sub.1-10 alkyl-O--CO--, C.sub.1-10 alkyl-O--CO--NH--, and C.sub.1-10 alkyl-S--;
- K is selected from the group consisting of halogen, C.sub.1-10 perfluoroalkyl, C.sub.1-10 alkoxy, NO.sub.2, CN, OH, CO.sub.2 H, amino, C.sub.1-10 alkylamino, C.sub.2-12 dialkylamino, C.sub.1-10 acyl, C.sub.1-10 alkoxy-CO--, and C.sub.1-10 alkyl-S--;
- AA.sub.2 is a side chain blocked or unblocked amino acid with the L configuration, D configuration, or no chirality at the .alpha.-carbon selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine, beta-alanine, norleucine, norvaline, alpha-aminobutyric acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperidine carboxylic acid), O-methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, NH.sub.2 --CH(CH.sub.2 CHEt.sub.2)--COOH, alpha-aminoheptanoic acid, NH.sub.2 --CH(CH.sub.2 -1-napthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -2-naphthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclohexyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopentyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclobutyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopropyl)-COOH, trifluoroleucine, and hexafluoroleucine;
- AA.sub.1 is a side chain blocked or unblocked amino acid with the L configuration, D configuration, or no chirality at the .alpha.-carbon selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfoxide, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine, beta-alanine, norleucine, norvaline, alpha-aminobutyric acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperidine carboxylic acid), O-methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, NH.sub.2 --CH(CH.sub.2 CHEt.sub.2)--COOH, alpha-aminoheptanoic acid, NH.sub.2 --CH(CH.sub.2 -1-napthyl)-COOH, NH.sub.2 CH(CH.sub.2 -2-napthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclohexyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopentyl)--COOH, NH.sub.2 --CH(CH.sub.2 -cyclobutyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopropyl)-COOH, trifluoroleucine, and hexafluoroleucine; and
- R.sub.4 is selected from the group consisting of C.sub.3-20 cyclized alkyl with an attached phenyl group, C.sub.1-20 alkyl with an attached phenyl group substituted with K, C.sub.1-20 alkyl with an attached phenyl group disubstituted with K, C.sub.1-20 alkyl with an attached phenyl group trisubstituted with K, C.sub.3-20 cyclized alkyl with an attached phenyl group substituted with K, C.sub.1-10 alkyl with a morpholine ring attached through nitrogen to the alkyl, C.sub.1-10 alkyl with a piperidine ring attached through nitrogen to the alkyl, C.sub.1-10 alkyl with a pyrrolidine ring attached through nitrogen to the alkyl, C.sub.1-20 alkyl with an OH group attached to the alkyl, --CH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.2 OH, C.sub.1-10 alkyl with an attached 4-pyridyl group, C.sub.1-10 alkyl with an attached 3-pyridyl group, C.sub.1-10 alkyl with an attached 2-pyridyl group, --NH--CH.sub.2 CH.sub.2 -(4-hydroxyphenyl), and --NH--CH.sub.2 CH.sub.2 -(3-indolyl).
- 4. A peptide ketoamide compound of the formula:
- M.sub.1 -AA.sub.2 -AARES-CO--NH--R.sub.4
- or a pharmaceutically acceptable salt, wherein
- AARES represents AA.sub.1,
- M.sub.1 represents H, NH.sub.2 --CO--, NH.sub.2 --CS--, NH.sub.2 --SO.sub.2 --, X--NH--CO--, X.sub.2 N--CO--, X--NH--CS--, X.sub.2 N--CS--, X--NH--SO.sub.2 --, X.sub.2 N--SO.sub.2 --, X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO--, or X--O--CS--;
- X is selected from the group consisting of C.sub.1-10 alkyl, C.sub.1-10 fluoroalkyl, C.sub.1-10 alkyl substituted with J, C.sub.1-10 fluoroalkyl substituted with J, 1-admantyl, 9-fluorenyl, phenyl, phenyl substituted with K, phenyl disubstituted with K, phenyl trisubstituted with K, naphthyl, naphthyl substituted with K, naphthyl disubstituted with K, naphthyl trisubstituted with K, C.sub.1-10 alkyl with an attached phenyl group, C.sub.1-10 alkyl with two attached phenyl groups, C.sub.1-10 alkyl with an attached phenyl group substituted with K, C.sub.1-10 alkyl with two attached phenyl groups substituted with K, C.sub.1-10 alkyl with an attached phenoxy group, and C.sub.1-10 alkyl with an attached phenoxy group substituted with K on the phenoxy group;
- J is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-10 alkoxy, C.sub.1-10 alkylamine, C.sub.2-12 dialkylamine, C.sub.1-10 alkyl-O--CO--, C.sub.1-10 alkyl-O--CO--NH--, and C.sub.1-10 alkyl-S--;
- K is selected from the group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10 perfluoroalkyl, C.sub.1-10 alkoxy, NO.sub.2, CN, OH, CO.sub.2 H, amino, C.sub.1-10 alkylamino, C.sub.2-12 dialkylamino, C.sub.1 -C.sub.10 acyl, C.sub.1-10 alkoxy-CO--, and C.sub.1-10 alkyl-S--;
- AA.sub.2 is a side chain blocked or unblocked amino acid with the L configuration, D configuration, or no chirality at the .alpha.-carbon selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine, beta-alanine, norleucine, norvaline, alpha-aminobutyric acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperidine carboxylic acid), O-methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, NH.sub.2 --CH(CH.sub.2 CHEt.sub.2)--COOH, alpha-aminoheptanoic acid, NH.sub.2 --CH(CH.sub.2 -1-napthyl)-COOH, NH.sub.2 CH(CH.sub.2 -2-napthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclohexyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopentyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclobutyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopropyl)-COOH, trifluoroleucine, and hexafluoroleucine;
- AA.sub.1 is a side chain blocked or unblocked amino acid with the L configuration, D configuration, or no chirality at the .alpha.-carbon selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfoxide, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine, beta-alanine, norleucine, norvaline, alpha-aminobutyric acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperidine carboxylic acid), O-methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, NH.sub.2 --CH(CH.sub.2 CHEt.sub.2)--COOH, alpha-aminoheptanoic acid, NH.sub.2 --CH(CH.sub.2 -1-napthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -2-napthyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclohexyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopentyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclobutyl)-COOH, NH.sub.2 --CH(CH.sub.2 -cyclopropyl)-COOH, trifluoroleucine, and hexafluoroleucine; and
- R.sub.4 is selected from the group consisting of C.sub.1-10 alkyl with a morpholine ring attached through nitrogen to the alkyl, C.sub.1-10 alkyl with a piperidine ring attached through nitrogen to the alkyl, C.sub.1-10 alkyl with a pyrrolidine ring attached through nitrogen to the alkyl, C.sub.1-20 alkyl with an OH group attached to the alkyl, --CH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.2 OH, C.sub.1-10 alkyl with an attached 4-pyridyl group, C.sub.1-10 alkyl with an attached 3-pyridyl group, C.sub.1-10 alkyl with an attached 2-pyridyl group, --NH--CH.sub.2 CH.sub.2 -(4-hydroxyphenyl), and --NH--CH.sub.2 CH.sub.2 -(3-indolyl).
- 5. A peptide ketoamide compound for inhibiting serine and cysteine proteases selected from the group consisting of:
- (a) Z-Leu-Abu-CONH--(CH.sub.2).sub.3 --N(CH.sub.2 CH.sub.2).sub.2 O(morpholino),
- (b) Z-Leu-Abu-CONH--(CH.sub.2).sub.2 OH,
- (c) Z-Leu-Abu-CONH--(CH.sub.2).sub.2 O(CH.sub.2).sub.2 OH,
- (d) Z-Leu-Abu-CONH--CH.sub.2 --C.sub.6 H.sub.3 (OCH.sub.3).sub.2, and
- (e) Z-Leu-Abu-CONH--CH.sub.2 --C.sub.4 H.sub.4 N (2-pyridyl).
Parent Case Info
This is a continuation of application Ser. No. 08/247,081 filed on May 20, 1994, now abandoned, which is a continuation of Ser. No. 08/118,997 filed on Sep. 9, 1993, now abandoned, which is a continuation of Ser. No. 07/815,073 filed on Dec. 27, 1991, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5514694 |
Powers |
May 1996 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
195212 |
Sep 1986 |
EPX |
363284 |
Apr 1990 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Hu, Arch. Biochem. Biophys., 281, pp. 271-274 (received in PTO Sep. 10, 1990). |
Burkhart, Tetrahedron Lett., 29, pp. 3433-3436 (1988). |
Continuations (3)
|
Number |
Date |
Country |
Parent |
247081 |
May 1994 |
|
Parent |
118997 |
Sep 1993 |
|
Parent |
815073 |
Dec 1991 |
|